Health · 2 views
Investigational immunotherapy nearly doubles overall survival compared with docetaxel in advanced squamous NSCLC
Patients with metastatic squamous non-small cell lung cancer (NSCLC) whose disease progressed following PD-(L)1 inhibitor therapy experienced a median overall survival of 18.5 months with the investigational anti-CTLA-4 antibody…
Summary
Patients with metastatic squamous non-small cell lung cancer (NSCLC) whose disease progressed following PD-(L)1 inhibitor therapy experienced a median overall survival of 18.5 months with the investigational anti-CTLA-4 antibody gotistobart, compared with 10.0 months for patients receiving docetaxel, according to updated findings from stage 1 of the Phase III PRESERVE-003 trial.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedCoverage Context
More from Health
Continue reading recent Health coverage
- What is aortic dissection? Symptoms, causes and how to lower riskContinue reading
- STAT+: RFK Jr. returns to his rootsContinue reading
- Why most emergency headache patients disappear into the dataContinue reading
- Three babies might have survived if hospital had acted over Lucy Letby concerns, inquiry findsContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow